Baiyang Pharmaceutical announced that revenue for the first half of 2026 was 3.56 billion yuan, down 5.11% year on year; net profit attributable to shareholders of listed companies was 225 million yuan, up 37.72% year on year, and 163 million yuan for the same period in 2025; net profit after deducting non-recurring profit and loss was 221 million yuan, up 24.58% year on year. The company plans to publicly issue H shares and list them on the main board of the Hong Kong Stock Exchange Limited.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.